West Pharma’s financial strength is solid, and the firm has historically managed a very strong balance sheet. As of year-end 2023, West had total debt outstanding of $206 million. West has ...

Adults with insulin-treated type 2 diabetes had a significant HbA1c decline at 13 weeks with use of the Omnipod 5 automated ...

West Pharmaceuticals stock drops 38% after ending glucose monitor contracts; CEO Eric Green says GLP-1 business will offset ...

A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Commercials run by Hims & Hers advertise prescription injectable weight-loss drugs without disclosing safety and risk information.

Not all weight loss programs are made equal—to reach a healthy, sustainable weight, personalized programs offer the best ...

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

The Janus Henderson Global Sustainable Equity Fund returned -5.88% for Q4 2024. Click here to read the full commentary.

The weight of being a Hollywood star can take a toll on a person’s weight.In an industry obsessed with physical appearance, a ...

Q4 2024 Earnings Call Transcript February 13, 2025 West Pharmaceutical Services, Inc. beats earnings expectations. Reported ...

Chronic pain is a worldwide epidemic that disproportionately affects women. These surgeons have found innovative solutions - ...